1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Norway Pharmaceuticals and Healthcare Report Q1 2016

Norway Pharmaceuticals and Healthcare Report Q1 2016

  • January 2016
  • -
  • Business Monitor International
  • -
  • 63 pages

Includes 3 FREE quarterly updates

BMI View: Norway's 2016 fiscal stimulus is expected to be positive in terms of supporting thepharmaceutical and healthcare sector growth trajectory Over the long term, policies aimed at promotingeconomic diversification away from energy exports are set to benefit the biotech and pharmaceutical sectordevelopment, which will remain a key policy priority A growing and ageing population and high per capitaexpenditure on medicine will ensure renewed opportunities for drugmakers over the forecast period despitethe small market sizeHeadline Expenditure ProjectionsPharmaceuticals: NOK2170bn (USD348bn) in 2014 to NOK2198bn (USD269bn) in 2015; +128% inlocal currency terms and -229% in US dollar terms Forecast broadly in line with last quarterHealthcare: NOK29821bn (USD4786bn) in 2014 to DKK30859bn (USD3872bn) in 2014; +35% inlocal currency terms and -212% in US dollar terms Forecast revised slightly downwards from last quarter

Table Of Contents

Norway Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Norway 2013-2019) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2011-2019) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 19
Prescription Drug Market Forecast 20
Pharmaceutical Trade Forecast 23
Table: Pharmaceutical Trade Data And Forecasts (Norway 2013-2019) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2013-2019) 25
Industry Risk/Reward Index 26
Western Europe Risk/Reward Index 26
Norway Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Pricing Regime 36
Reimbursement Regime 37
Market Overview 40
Healthcare Sector 41
Table: Healthcare Resources (Norway 2009-2014) 42
Table: Healthcare Personnel (Norway 2009-2014) 42
Table: Healthcare Activity (Norway 2009-2014) 43
Research and Development 43
Clinical Trials 45
Epidemiology 45
Competitive Landscape 47
Table: The Top 25 Pharmaceutical Companies In Norway 48
Table: Multinational Market Activity 50
Demographic Forecast 52
Table: Population Headline Indicators (Norway 1990-2025) 53
Table: Key Population Ratios (Norway 1990-2025) 53
Table: Urban/Rural Population and Life Expectancy (Norway 1990-2025) 54
Table: Population By Age Group (Norway 1990-2025) 54
Table: Population By Age Group % (Norway 1990-2025) 55
Glossary 57
Methodology 59
Pharmaceutical Expenditure Forecast Model 59
Healthcare Expenditure Forecast Model 59
Notes On Methodology 60
Risk/Reward Index Methodology 61
Index Overview 62
Table: Pharmaceutical Risk/Reward Index Indicators 62
Indicator Weightings 63

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.